Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial.

Saved in:
Bibliographic Details
Title: Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial.
Authors: Riggle BA; Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Chamzas A; Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA., Gopalakrishnan M; Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA., Nyirenda OM; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Nampota-Nkomba N; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.; Department of Internal Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi., Mallewa JE; Department of Internal Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi., Masonga R; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Manyozo C; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Zuze K; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Liomba AM; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi., Alt J; Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA., Rais R; Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA., Slusher B; Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA., Moodley N; Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Miller LH; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Pierce SK; Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., O'Brien NF; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.; Department of Pediatrics, Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., Laurens MB; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Postels DG; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.; Division of Neurology, The George Washington University, Children's National Hospital, Washington, District of Columbia, USA.
Source: The Journal of infectious diseases [J Infect Dis] 2026 May 15; Vol. 233 (5), pp. e1226-e1237.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1537-6613
DOI:10.1093/infdis/jiag121